Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RT036
- Development stage
- Phase 2
- Lead developer
- Shanghai Ruotuo Biotechnology
- Administration
- Parenteral
01
Overview
RT036 is an investigational biologic being developed by Shanghai Ruotuo Biotechnology, a joint venture between Anwita Biosciences and Junshi Biosciences. It is currently undergoing evaluation in a Phase I/II clinical trial in China for the treatment of advanced malignant solid tumors. The open-label study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of RT036 injection in adult patients with advanced solid tumors who have progressed after standard systemic therapies.
Beyond the preview
Go deeper on RT036.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RT036.